Skip to main content
. Author manuscript; available in PMC: 2016 Jun 28.
Published in final edited form as: Leukemia. 2015 Dec 28;30(5):1086–1093. doi: 10.1038/leu.2015.350

Figure 2. Venetoclax is highly active in combination therapy.

Figure 2

KMS18, 8226, MM.1s, KMS11, and OPM2 were treated with indicated concentrations of venetoclax alone or in combination with the indicated concentration of A. Carfilzomib, or C. Dexamethasone for 24 h. B. KMS18 was treated with Carfilzomib for 24 h and protein lysates subjected to input analysis and co-immunoprecipitation as described in Figure 1. Densitometry measurements of the Bim bound to Mcl-1, Bcl-xL, and Bcl-2 under each treatment condition is represented as pie charts and the size of the pie is proportional to the total amount of bound Bim present under each treatment, relative to the control (1.0). Carfilzomib = 1.05. The data in A and C are presented as the means (±SE) of 3 independent experiments. The blot in B is representative of three experiments and densitometry average of two experiments.